Biotech entity
pharma is the sole category represented across all 2 tracked stories. Codexis is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. That works out to roughly 1.6 stories per week across a 9-day span. At 5, the average consequence score sits below the same-window beat average of 6.1.
Last mentioned: Mar 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 2 tracked stories. Codexis is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. That works out to roughly 1.6 stories per week across a 9-day span. At 5, the average consequence score sits below the same-window beat average of 6.1. They are less corroborated than the beat average, carrying 2 original sources each against 3.1 for the same window. ECO Synthesis appears in 2 tracked Biotech stories published from March 16, 2026 through March 24, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 151 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ECO Synthesis. Shared-story counts are live from our verified record — not editorial picks.
Analyst Sentiment Review
Major firms maintain ratings, citing steady execution of the strategic pivot.
2026 Guidance Issued
Management outlines $72M-$76M revenue target driven by ECO Synthesis.
Q4 2025 Earnings Release
Codexis reports significant beats on both top and bottom lines.
Codexis (CDXS) has maintained steady analyst sentiment following a strong Q4 2025 performance that exceeded revenue and earnings expectations. The company’s strategic pivot toward its ECO Synthesis platform for RNA manufacturing is gaining commercial traction, supported by a 2026 revenue target of $72M–$76M.
Source: finance.yahoo.com · insidermonkey.com
Wall Street Zen has upgraded the stock ratings for Codexis (CDXS) and Enovis (ENOV), signaling increased confidence in their long-term strategic pivots. The upgrades follow robust quarterly performances and the unveiling of ambitious 2026 revenue targets driven by high-margin technological innovations.
Source: dailypolitical.com · themarketsdaily.com
ECO Synthesis is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
